Company Overview
Fate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing programmed cellular immunotherapies designed to treat cancer and immune disorders within the United States and international markets. The organization functions within the Healthcare sector, specifically under the Biotechnology industry, where its primary focus is on advancing chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates such as FT836. The company currently maintains a market capitalization of $141.84M, generates annual revenue of $6.65M, and employs a workforce of 161 individuals. These financial figures indicate that Fate Therapeutics operates with a relatively modest market capitalization and revenue stream, positioning it as a smaller-cap entity that relies heavily on future clinical development milestones to potentially achieve significant valuation expansion rather than established commercial cash flows.
Financial Health
The company reported a trailing twelve-month revenue of $6.65M, yet it recorded a net income of $-136,315,008 and an EBITDA of $-133,703,000, revealing a substantial gap where operational expenses and research costs significantly exceed generated revenue. This disparity highlights a cost structure typical of clinical-stage biotechnology firms that are burning cash to fund development pipelines before achieving commercial product approval. Furthermore, the free cash flow stands at $-51,558,500, indicating that the company is currently consuming cash reserves to sustain its operations and R&D activities without generating positive internal cash generation. The margin profile reflects this financial reality, with a gross margin of 0.0%, an operating margin of -2455.9%, and a profit margin of 0.0%, all of which signal that the business is not yet profitable and is operating at a deep loss on an operational basis. In terms of liquidity and leverage, the company holds $203.66M in cash against $77.85M in debt, supported by a debt-to-equity ratio of 37.58 and a current ratio of 5.79. While the high current ratio suggests robust short-term liquidity and the ability to cover obligations with current assets, the negative net income and EBITDA demonstrate that management has not yet achieved return on equity of -51.8% or return on assets of -24.1%, indicating that management effectiveness in generating returns on capital is currently compromised by heavy investment phases.
Valuation Assessment
Valuation metrics for Fate Therapeutics present a complex picture given the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -1.16, implying that traditional earnings-based valuation models are not applicable due to the absence of positive earnings and the expectation of continued losses. The price-to-book ratio is recorded at 0.68, suggesting that the market is valuing the company's equity at less than its book value, which often occurs in speculative biotech stocks where intangible assets and future pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 21.34 and an EV/EBITDA of -0.12 indicate that investors are pricing the stock primarily on revenue generation potential rather than current profitability or earnings power. Regarding trading ranges, the 52-week high is $1.94 and the 52-week low is $0.66, meaning the current price sits within a range where the stock has experienced significant volatility but remains below its recent peak. The beta value of 2.23 indicates that the stock is highly volatile and tends to move more than twice as much as the broader market, reflecting the high risk associated with clinical-stage biopharmaceutical investments.
Growth & Income
The company experienced a revenue growth rate of -26.4% year over year, while earnings growth is listed as N/A, indicating that the decline in revenue has been accompanied by continued negative earnings rather than a transition to profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all financial resources are necessarily reinvested into research and development rather than distributed to shareholders. The absence of a dividend yield confirms that the company follows a growth-oriented strategy typical of early-stage biotechnology firms that prioritize pipeline advancement over income generation for investors. Overall, the growth and income profile of Fate Therapeutics is characterized by negative revenue momentum and a complete reliance on capital markets or cash reserves to fund operations, with no current income stream for shareholders.